

Provider Led Entity

CDI Quality Institute AUC Questions: Multiple Sclerosis

07/17/2018

Patient/Problem: Appropriateness of advanced imaging procedures in patients with the following clinical presentations or diagnoses:

- First episode of neurologic symptoms with clinical suspicion of inflammation and/or demyelination in the central nervous system (Clinically Isolated Syndrome), including:
 - New optic neuritis, diplopia, or other vision problem
 - New focal neurologic deficit/myelopathic symptoms
 - New ataxia and/or brainstem symptoms
- Surveillance of suspected MS not meeting radiological (and laboratory) criteria
- Surveillance of suspected neuromyelitis optica not meeting radiological (and laboratory) criteria
- Known MS with new or recurrent neurological or myelopathic symptoms (MS flare)
- Known neuromyelitis optica with new or recurrent neurological or myelopathic symptoms
- Monitoring of treatment response in patients with known MS
- Monitoring of treatment response in patients with known neuromyelitis optica.

For patients > 18 years of age, in a community outpatient setting, and for the purposes of diagnosis.

Interventions:

Advanced testing (MRI, MRA, CT, CTA, Nuclear medicine w/ or w/o SPECT, PET, PET/CT)

Comparison: Gold standard (Clinical evaluation and oligoclonal band testing)

Outcome: Diagnostic yield, Diagnostic accuracy, positive predictive value, effect on patient management, surgical rate and/or patient outcomes

Exclusions:

- Other types of demyelinating disease
- Pregnant patients and
- Pediatric patients.